Fredun Pharmaceuticals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Fredun Pharmaceuticals Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹-8 of operating cash. Lower than 95% of Healthcare companies in India.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 93% of Healthcare companies in India.
- Shareholder Slice Ratio: Share count rose 21% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 91% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹-8Over the last 3 years, every ₹100 of reported profit came with ₹-8 of operating cash.
Lower than 95% of Healthcare companies in India.
Self-Funding Ratio
-0.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 93% of Healthcare companies in India.
Cash Locked Ratio
₹42For every ₹100 of sales, ₹42 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹45 tied up three years earlier.
More money tied up than 83% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹6Sales grew 131% in 3 years; of every extra ₹100 of sales, ₹6 became extra profit.
Lower than 78% of Healthcare companies in India.
Asset Productivity Ratio
+131% / +150%In 3 years sales changed by +131% while total assets changed by +150%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.1×Debt due within a year is covered 0.1 times by its yearly operating cash.
Lower than 86% of Healthcare companies in India.
Cash Cushion Ratio
−7%Debt, after subtracting cash, equals 7% of its market value (net debt).
Lower than 72% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 83% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 77% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Fredun Pharmaceuticals Limited owes ₹0.56 for every ₹1 it owns. Net profit rose 65% in the year to Mar 2026, and grew 45% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
50.5Investors pay ₹50.5 for every ₹1 of Fredun Pharmaceuticals Limited's yearly profit, higher than 68% of Healthcare companies in India.
P/B ratio
8.44The share price is 8.44 times Fredun Pharmaceuticals Limited's book value per share, higher than 78% of Healthcare companies in India.
Market cap
₹2,376 CrThe total market value of all of Fredun Pharmaceuticals Limited's shares at today's price (share price × number of shares), smaller than 62% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹282 CrWhat Fredun Pharmaceuticals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹164.86Net worth divided by the number of shares. The share price of ₹1,391 is 8.4 times this, which is the P/B above.
Return on equity (ROE)
16.2%Fredun Pharmaceuticals Limited earned 16.2% on its shareholders' money over the last year, higher than 62% of Healthcare companies in India.
Owes vs Owns
0.56×Fredun Pharmaceuticals Limited owes ₹0.56 for every ₹1 it owns (moderate), higher than 91% of Healthcare companies in India.
Dividend yield
0.05%Fredun Pharmaceuticals Limited pays 0.05% of its share price as dividends a year, lower than 96% of dividend-paying Healthcare companies in India.
Revenue growth
+40%Revenue rose 40% in the year to Mar 2026, and grew 32% a year on average over 3 years.
Profit growth
+65%Net profit rose 65% in the year to Mar 2026, and grew 45% a year on average over 3 years.
Profit margin
5.2%Fredun Pharmaceuticals Limited keeps ₹5 of every ₹100 of revenue as net profit.
Cash quality
0.4×Cash from Fredun Pharmaceuticals Limited's business was 0.4× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
2.5×Fredun Pharmaceuticals Limited's operating profit covered its interest costs 2.5 times in the year to Mar 2026.
Cash vs debt
Net debtFredun Pharmaceuticals Limited had ₹177 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Fredun Pharmaceuticals Limited's P/E ratio?
Investors pay ₹50.5 for every ₹1 of Fredun Pharmaceuticals Limited's yearly profit, higher than 68% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Fredun Pharmaceuticals Limited: ₹2,376 Cr ÷ ₹282 Cr (31 Mar 2026) = 8.4.
What is Fredun Pharmaceuticals Limited's return on equity?
Fredun Pharmaceuticals Limited earned 16.2% on its shareholders' money over the last year, higher than 62% of Healthcare companies in India.
How much does Fredun Pharmaceuticals Limited owe compared with what it owns?
Fredun Pharmaceuticals Limited owes ₹0.56 for every ₹1 it owns (moderate), higher than 91% of Healthcare companies in India.
Does Fredun Pharmaceuticals Limited pay a dividend?
Yes. Fredun Pharmaceuticals Limited pays 0.05% of its share price as dividends a year, lower than 96% of dividend-paying Healthcare companies in India.
Is Fredun Pharmaceuticals Limited's revenue growing?
Revenue rose 40% in the year to Mar 2026, and grew 32% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.